Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VNDA Stock Forecast 2026-2027
$5.45
Current Price
$351.79M
Market Cap
Buy 3
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to VNDA Price Targets
+285.3%
To High Target of $21.00
+156.9%
To Median Target of $14.00
+37.6%
To Low Target of $7.50
VNDA Price Momentum
-12.7%
1 Week Change
-8.6%
1 Month Change
+12.1%
1 Year Change
-38.2%
Year-to-Date Change
-45.2%
From 52W High of $9.94
+31.6%
From 52W Low of $4.14
📊 TOP ANALYST CALLS
Did VNDA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Vanda Pharmaceuticals is one of their latest high-conviction picks.
Latest VNDA Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, VNDA has a bullish consensus with a median price target of $14.00 (ranging from $7.50 to $21.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $5.45, the median forecast implies a 156.9% upside. This outlook is supported by 3 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 285.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VNDA Analyst Ratings
3
Buy
1
Hold
0
Sell
VNDA Price Target Range
Low
$7.50
Average
$14.00
High
$21.00
Current: $5.45
Latest VNDA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VNDA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 11, 2026 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $21.00 |
| Mar 5, 2026 | Truist Securities | Buy | Initiates | $N/A | |
| Feb 23, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jan 5, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Dec 31, 2025 | B. Riley Securities | Buy | Maintains | $N/A | |
| Dec 31, 2025 | Jefferies | Hold | Maintains | $N/A | |
| Nov 19, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 5, 2025 | B. Riley Securities | Buy | Initiates | $N/A | |
| Oct 30, 2025 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Aug 21, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 14, 2025 | Cantor Fitzgerald | Olivia Brayer | Overweight | Assumes | $13.00 |
| May 7, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 1, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 18, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 4, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 28, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 21, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 23, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 31, 2024 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Aug 1, 2024 | Cantor Fitzgerald | Overweight | Maintains | $N/A |
Vanda Pharmaceuticals Inc. (VNDA) Competitors
The following stocks are similar to Vanda Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
VNDA
Vanda Pharmaceuticals
mkt cap
375.25M
Vanda Pharmaceuticals Inc. (VNDA) Financial Data
Vanda Pharmaceuticals Inc. has a market capitalization of $351.79M with a P/E ratio of 126.0x. The company generates $217.78M in trailing twelve-month revenue with a -110.0% profit margin.
Revenue growth is +3.4% quarter-over-quarter, while maintaining an operating margin of -97.1% and return on equity of -60.5%.
Valuation Metrics
Market Cap
$351.79M
Enterprise Value
$171.58M
P/E Ratio
126.0x
PEG Ratio
2.0x
Price/Sales
1.7x
Growth & Margins
Revenue Growth (YoY)
+3.4%
Gross Margin
+93.9%
Operating Margin
-97.1%
Net Margin
-110.0%
EPS Growth
+3.4%
Financial Health
Cash/Price Ratio
+61.7%
Current Ratio
2.2x
Debt/Equity
4.7x
ROE
-60.5%
ROA
-18.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Vanda Pharmaceuticals Inc. (VNDA) Business Model
About Vanda Pharmaceuticals Inc.
What They Do
Develops therapies for unmet medical needs.
Business Model
The company generates revenue by developing and commercializing specialized biopharmaceuticals targeting significant medical needs, particularly in areas like sleep-wake disorders and psychiatric conditions. Its portfolio includes marketed products such as HETLIOZ and Fanapt, while also advancing a diverse pipeline of innovative treatments aimed at rare and complex conditions.
Additional Information
Founded in 2002 and based in Washington, DC, the company has a global presence, primarily selling its products in the United States, but also in Israel, Europe, and Canada. Vanda Pharmaceuticals focuses on addressing rare disorders and conditions with few available treatment options, positioning itself strategically in the biopharmaceutical market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
533
CEO
Dr. Mihael H. Polymeropoulos M.D.
Country
United States
IPO Year
2006
Website
www.vandapharma.comVanda Pharmaceuticals Inc. (VNDA) Latest News & Analysis
Latest News
Quick Summary
Vanda Pharmaceuticals announced its medication NEREUS™ (tradipitant) will sponsor entry No. 47 in the NTT IndyCar Series, marking its first approval for motion-induced vomiting in 47 years.
Why It Matters
Vanda Pharmaceuticals' new drug approval and sponsorship in a high-profile racing series enhance brand visibility, potentially boosting sales and investor confidence in future growth.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) will participate in a fireside chat at the B. Riley Securities Mind, Muscle & Vision Summit on July 16, 2026, in Boston.
Why It Matters
Vanda Pharmaceuticals' participation in a prominent summit could signal potential developments or partnerships, impacting investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Vanda Pharmaceuticals' investigational therapy VCA-894A for Charcot-Marie-Tooth disease type 2S has received Rare Pediatric Disease Designation from the FDA.
Why It Matters
FDA granting Rare Pediatric Disease Designation to Vanda's therapy enhances its market potential and may lead to faster approval, boosting investor confidence in the company's future growth.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Vanda Pharmaceuticals' imsidolimab received orphan drug designation from Japan's MHLW for treating generalized pustular psoriasis, targeting a significant unmet medical need.
Why It Matters
Vanda Pharmaceuticals' orphan drug designation for imsidolimab enhances its market potential in treating GPP, potentially increasing revenue and investor confidence in the company's future growth.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Vanda Pharmaceuticals is rated a buy due to new drug approvals and strong growth potential. However, it faces weak earnings, high R&D costs, and no expected profitability until 2030.
Why It Matters
Vanda Pharmaceuticals shows strong growth potential and balance sheet strength, yet faces challenges with ongoing losses and high costs. Investors may weigh short-term risks against long-term gains.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Vanda Pharmaceuticals Inc. (VNDA) has released its Q1 2026 earnings call transcript, detailing its financial performance and strategic updates.
Why It Matters
The Vanda Pharmaceuticals Q1 2026 earnings call reveals financial performance, guiding future expectations, which directly impacts stock valuations and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About VNDA Stock
What is Vanda Pharmaceuticals Inc.'s (VNDA) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Vanda Pharmaceuticals Inc. (VNDA) has a median price target of $14.00. The highest price target is $21.00 and the lowest is $7.50.
Is VNDA stock a good investment in 2027?
According to current analyst ratings, VNDA has 3 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.45. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VNDA stock?
Wall Street analysts predict VNDA stock could reach $14.00 in the next 12 months. This represents a 156.9% increase from the current price of $5.45. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Vanda Pharmaceuticals Inc.'s business model?
The company generates revenue by developing and commercializing specialized biopharmaceuticals targeting significant medical needs, particularly in areas like sleep-wake disorders and psychiatric conditions. Its portfolio includes marketed products such as HETLIOZ and Fanapt, while also advancing a diverse pipeline of innovative treatments aimed at rare and complex conditions.
What is the highest forecasted price for VNDA Vanda Pharmaceuticals Inc.?
The highest price target for VNDA is $21.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 285.3% increase from the current price of $5.45.
What is the lowest forecasted price for VNDA Vanda Pharmaceuticals Inc.?
The lowest price target for VNDA is $7.50 from at , which represents a 37.6% increase from the current price of $5.45.
What is the overall VNDA consensus from analysts for Vanda Pharmaceuticals Inc.?
The overall analyst consensus for VNDA is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $14.00.
How accurate are VNDA stock price projections?
Stock price projections, including those for Vanda Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 3:25 AM UTC